<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05029960</url>
  </required_header>
  <id_info>
    <org_study_id>UBRT21074</org_study_id>
    <nct_id>NCT05029960</nct_id>
  </id_info>
  <brief_title>Tolerability and Activity of Brivaracetam (BRV) in Patients With Diffuse Gliomas</brief_title>
  <official_title>Tolerability and Activity of Brivaracetam (BRV) in Patients With Diffuse Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the study medication, brivaracetam, is&#xD;
      tolerable and safe for patients with brain tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, subjects will receive usual treatment for their brain tumor. In addition, they&#xD;
      will be given brivaracetam at a dose of 50 mg twice daily.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 31, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of Brivaracetam</measure>
    <time_frame>6 Months</time_frame>
    <description>Evaluate adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Voluntariness for study participation</measure>
    <time_frame>6 Months</time_frame>
    <description>Number of people that declined to participate</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Brain Tumor</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brivaracetam at a dose of 50 mg twice daily for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brivaracetam</intervention_name>
    <description>Dose of 50 mg twice daily for 6 months</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥ 18 years with pathologic diagnosis of a supratentorial diffuse astrocytic or&#xD;
             oligodendroglial tumor&#xD;
&#xD;
          -  Patients must be able to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A pre-existing seizure disorder or epilepsy syndrome prior to tumor diagnosis&#xD;
&#xD;
          -  Active maintenance therapy with an antiepileptic seizure drug (AED) prior to diagnosis&#xD;
             of tumor&#xD;
&#xD;
          -  Patients who have experienced an epileptic seizure as the presenting symptom of their&#xD;
             brain tumor&#xD;
&#xD;
          -  Predicted life expectancy of less than 6 months from the time of screening&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Patients with clinically significant hepatic disease (elevated aminotransferases&#xD;
             [bilirubin, alkaline phosphatase] &gt; 3 times upper limit normal)&#xD;
&#xD;
          -  Patients with stage 4 or greater renal disease (GFR &lt;30 mL/min/1.73 m2)&#xD;
&#xD;
          -  Patients who are unable to swallow a tablet&#xD;
&#xD;
          -  Patients with active suicidal ideation or a history of suicide attempt or other&#xD;
             serious psychiatric disorder having required hospitalization within the previous 2&#xD;
             years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Thomas Wychowski</last_name>
    <phone>585-275-4401</phone>
    <email>Thomas_Wychowski@URMC.Rochester.edu</email>
  </overall_contact>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 25, 2021</study_first_submitted>
  <study_first_submitted_qc>August 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2021</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Thomas Wychowski</investigator_full_name>
    <investigator_title>Associate Professor - Department of Neurology , Epilepsy (SMD)</investigator_title>
  </responsible_party>
  <keyword>Brain Tumor</keyword>
  <keyword>Brivaracetam</keyword>
  <keyword>Epilepsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brivaracetam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

